# Zepzelca (lurbinectedin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lurbinectedin

> The FDA approved Zepzelca (lurbinectedin), sponsored by Jazz Pharmaceuticals plc (JAZZ), on June 15, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Zepzelca (lurbinectedin) |
| Codes |  |
| Sponsor | Jazz Pharmaceuticals plc (JAZZ) https://sec-api.dev/companies/jazz/catalysts |
| Indications | [Extensive-stage Small-cell Lung Cancer](https://sec-api.dev/indications/extensive-stage-small-cell-lung-cancer) |
| Modality |  |
| FDA designations | accelerated, orphan, priority review |

## Timeline

### June 15, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213702 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200615, review_priority PRIORITY; sponsor_name JAZZ; product ZEPZELCA (LURBINECTEDIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213702%22

### Oct 2024: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2025-02-26, last confirmed 2026-05-05.
- SEC Form 10-Q (accession 0001232524-25-000074): "In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000074/jazz-20250930.htm
- SEC Form 10-Q (accession 0001232524-25-000063): "In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000063/jazz-20250630.htm
- SEC Form 10-Q (accession 0001232524-25-000027): "In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000027/jazz-20250331.htm
- SEC Form 10-K (accession 0001232524-25-000011): "In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252425000011/jazz-20241231.htm
- SEC Form 10-Q (accession 0001232524-26-000025): "In October 2024, we announced positive top-line results from the Phase 3 IMforte trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000025/jazz-20260331.htm
- SEC Form 10-K (accession 0001232524-26-000013): "In October 2024, we announced positive top-line results from the Phase 3 IMforte trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm
- SEC Form 10-K (accession 0001232524-26-000013): "In October 2024, we announced positive top-line results from the Phase 3 IMforte trial showing a statistically significant and clinically meaningful benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm

### 1H 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004989): "EmpowHER late-line BC trial is enrolling approach to capital Meaningful growth opportunity in IH allocation Zepzelca Treatment of choice in 2L SCLC Expect to submit sNDA for 1L ES-SCLC in 1H25 Near universal adoption in U.S. pediatric protocols" https://www.sec.gov/Archives/edgar/data/1232524/000119312525004989/d699726dex991.htm

### October 2, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213702 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20251002, review_priority PRIORITY; sponsor_name JAZZ; product ZEPZELCA (LURBINECTEDIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213702%22

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Extensive-stage Small-cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07459634 (A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT07459634

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Extensive-stage Small-cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07459634 (A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." https://clinicaltrials.gov/study/NCT07459634

## Same indication

- [Bnt327 dose level 1 (dl1)](https://sec-api.dev/pdufa/bnt327-dose-level-1-dl1) (BNTX)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lurbinectedin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zepzelca (lurbinectedin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lurbinectedin

```bibtex
@misc{secapidev_pdufa_lurbinectedin_20261116,
  title        = {Zepzelca (lurbinectedin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lurbinectedin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lurbinectedin_20261116","title":"Zepzelca (lurbinectedin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lurbinectedin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
